| Literature DB >> 35208717 |
Rikio Kirisawa1, Rika Kato1, Koichi Furusaki2, Takashi Onodera3.
Abstract
We investigated the virucidal effects in solution of a new type of disinfectant, calcium bicarbonate mesoscopic crystals, designated CAC-717, against various types of virus. CAC-717 in solution is alkaline (pH 12.4) and has a self-electromotive force that generates pulsed electrical fields. Upon application to human skin, the pH of the solution becomes 8.4. CAC-717 contains no harmful chemicals and is thus non-irritating and harmless to humans and animals. Its virucidal effects were tested against six types of animal virus: enveloped double-strand (ds)-DNA viruses, non-enveloped ds-DNA viruses, non-enveloped single strand (ss)-DNA viruses, enveloped ss-RNA viruses, non-enveloped ss-RNA viruses, and non-enveloped ds-RNA viruses. The treatment resulted in a reduction in viral titer of at least 3.00 log10 to 6.38 log10. Fetal bovine serum was added as a representative organic substance. When its concentration was ≥20%, the virucidal effect of CAC-717 was reduced. Real-time PCR revealed that CAC-717 did not reduce the quantity of genomic DNA of most of the DNA viruses, but it greatly reduced that of the genomic RNA of most of the RNA viruses. CAC-717 may therefore be a useful biosafe disinfectant for use against a broad range of viruses.Entities:
Keywords: SARS-CoV-2; animal viruses; calcium bicarbonate; disinfectant; foot-and-mouth disease virus; mesoscopic crystals; virucidal activity
Year: 2022 PMID: 35208717 PMCID: PMC8877192 DOI: 10.3390/microorganisms10020262
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Virus strains used in this study.
| Envelope | Genome | Family | Genus | Virus | Strain | Reference |
|---|---|---|---|---|---|---|
| + | ds-DNA |
|
| infectious bovine rhinotracheitis virus (IBRV) | Los Angeles | [ |
| pseudorabies virus (PrV) | MY-1 | [ | ||||
| canine herpesvirus 1 (CHV-1) | GCH-1 | [ | ||||
| equine herpesvirus 1 (EHV-1) | HH1 | [ | ||||
| - | ds-DNA |
|
| bovine adenovirus 7 (BAdV-7) | Fukuroi | [ |
| - | ss-DNA |
|
| canine parvovirus 2 (CPV-2) | 97-008 | this study |
| + | ss-RNA |
|
| bovine parainfluenza virus 3 (BPIV-3) | BN-1 | [ |
|
| bovine respiratory syncytial virus (BRSV) | rs-52 | [ | |||
|
| canine distemper virus (CDV) | KDK-1 | [ | |||
|
| Newcastle disease virus (NDV) | Miyadera | [ | |||
| + | ss-RNA |
|
| vesicular stomatitis virus (VSV) | New Jersey | [ |
| + | ss-RNA |
|
| SARS-CoV-2 | JPN/TY/WK-521 | [ |
| bovine coronavirus (BCoV) | Kakegawa | [ | ||||
| + | ss-RNA |
|
| swine influenza A virus (pdm09, H1N1) (SwIV) | A/swine/Ibaraki/46/ | [ |
| equine influenza A virus (H3N8) (EqIV) | A/Equine/Hayakita/ | this study | ||||
| + | ss-RNA |
|
| bovine viral diarrhea virus I (BVDV-I) | Nose | [ |
| bovine viral diarrhea virus II (BVDV-II) | KZ-91CP | [ | ||||
| - | ss-RNA |
|
| foot-and-mouth disease virus (FMDV) | A/Vietnam/HSMD05/2003 | this study |
| O/Vietnam/HSMD03/2005 | this study | |||||
| Asia1/Vietnam/HSMD04/2005 | this study | |||||
| bovine rhinitis B virus (BRBV) | EC11 | [ | ||||
| - | ss-RNA |
|
| feline calicivirus (FCV) | F9 | [ |
| - | ds-RNA |
|
| bovine rotavirus (BRoV) | strain 22R (G6P [ | [ |
|
| bulbul orthoreovirus (BuORV) | Pycno-1 | [ |
Virucidal effects of CAC-717 on various DNA viruses. Viral titer is shown as log10 TCID50/25 μL (mean ± SE). Values are representative values from two separate experiments.
| Viruses | Solution | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| CAC-717 | CAC-717 + HEPES 1 | Tap Water | Maintenance Medium | ||||||
| 2 s | 10 s | 30 s | 1 min | 15 min | 30 min & 60 min | 60 min | 60 min | 60 min | |
| Enveloped | |||||||||
|
| |||||||||
| IBRV | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | 6.71 ± 0.13 | 6.71 ± 0.13 | 6.96 ± 0.13 |
| PrV | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | 4.83 ± 0.25 | 4.83 ± 0.00 | 4.96 ± 0.13 |
| CHV-1 | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | 3.33 ± 0.25 | 2.96 ± 0.13 | 3.71 ± 0.13 |
| EHV-1 | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | 4.83 ± 0.25 | 4.96 ± 0.13 | 4.96 ± 0.13 |
| Non-enveloped | |||||||||
|
| |||||||||
| BAdV-7 | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | 6.46 ± 0.13 | 6.33 ± 0.25 | 6.21 ± 0.13 |
|
| |||||||||
| CPV-2 | 2.96 ± 0.13 | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | 3.71 ± 0.13 | 3.46 ± 0.13 | 3.58 ± 0.00 |
1 Nine volumes of CAC-717 were pretreated with one volume of 1.0 M HEPES buffer (pH 7.2). * A reduction in viral titer of ≥4 log10 relative to treatment with maintenance medium; ** A reduction in viral titer of ≥3 log10 relative to treatment with maintenance medium.
Virucidal effects of CAC-717 on various RNA viruses. Viral titer is shown as log10 TCID50/25 μL (mean ± SE). Values are representative values from two separate experiments.
| Viruses | Solution | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| CAC-717 | CAC-717 + HEPES 1 | Tap Water | Maintenance Medium | ||||||
| 2 s | 10 s | 30 s | 1 min | 15 min | 30 min and 60 min | 60 min | 60 min | 60 min | |
| Enveloped | |||||||||
|
| |||||||||
| BPIV-3 | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | 6.21 ± 0.38 | 6.33 ± 0.25 | 6.58 ± 0.00 |
| BRSV | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | 3.58 ± 0.00 | 3.58 ± 0.00 | 3.83 ± 0.00 |
| CDV | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | 3.58 ± 0.25 | 3.46 ± 0.13 | 3.58 ± 0.00 |
| NDV | 4.21 ± 0.13 | 4.08 ± 0.00 | 3.71 ± 0.13 | 3.46 ± 0.13 | 2.08 ± 0.00 ** | ≤0.58 * | 5.71 ± 0.13 | 5.33 ± 0.25 | 5.46 ± 0.13 |
|
| |||||||||
| VSV | 6.08 ± 0.00 | 6.25 ± 0.25 | 6.08 ± 0.00 | 5.46 ± 0.13 | 2.08 ± 0.25 * | ≤0.58 * | 6.33 ± 0.00 | 5.33 ± 0.00 | 6.08 ± 0.25 |
|
| |||||||||
| SARS-CoV-2 | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | 4.46 ± 0.13 | 4.46 ± 0.13 | 4.58 ± 0.00 |
| BCoV | ≤0.58 * | ≤0.5 *8 | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | 5.08 ± 0.00 | 5.33 ± 0.25 | 5.33 ± 0.00 |
|
| |||||||||
| SwIV (H1N1) | 2.83 ± 0.25 | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | 4.83 ± 0.25 | 5.08 ± 0.25 | 5.21 ± 0.13 |
| EqIV (H3N8) | 3.08 ± 0.00 | 1.46 ± 0.13 | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | 3.33 ± 0.00 | 3.21 ± 0.13 | 3.83 ± 0.00 |
|
| |||||||||
| BVDV-I | 4.58 ± 0.00 | 4.08 ± 0.00 | 3.83 ± 0.00 | 3.83 ± 0.25 | 1.96 ± 0.13 | ≤0.58 * | 4.21 ± 0.13 | 4.33 ± 0.00 | 4.71 ± 0.13 |
| BVDV-II | 4.58 ± 0.00 | 4.33 ± 0.00 | 4.46 ± 0.13 | 4.71 ± 0.13 | 2.46 ± 0.13 | ≤0.58 * | 4.96 ± 0.13 | 4.71 ± 0.13 | 4.71 ± 0.13 |
| Non-enveloped | |||||||||
|
| |||||||||
| FMDV type A | ≤0.5 *,2 | 5.00 ± 0.13 | 5.38 ± 0.13 | ||||||
| type O | ≤0.5 **,2 | 4.25± 0.00 | 4.00 ± 0.00 | ||||||
| type Asia 1 | ≤0.5 *,2 | 4.00± 0.00 | 4.63 ± 0.13 | ||||||
| BRBV | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | 4.21 ± 0.13 | 4.21 ± 0.13 | 4.71 ± 0.13 |
|
| |||||||||
| FCV | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | 7.08 ± 0.25 | 6.33 ± 0.00 | 6.58 ± 0.00 |
|
| |||||||||
| BRoV | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | 4.83 ± 0.00 | 4.58 ± 0.00 | 4.96 ± 0.13 |
| BuORV | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | ≤0.58 ** | 3.83 ± 0.00 | 3.71 ± 0.13 | 3.96 ± 0.13 |
1 Nine volumes of CAC-717 were pretreated with one volume of 1.0 M HEPES buffer (pH 7.2). 2 Viral titers after incubation for 60 min; * A reduction in viral titer of ≥4 log10 relative to treatment with maintenance medium; ** A reduction in viral titer of ≥3 log10 relative to treatment with maintenance medium.
Effect of FBS on the virucidal effects of CAC-717 on IBRV as a representative enveloped virus and BAdV-7 as a representative non-enveloped virus.
| Viruses | FBS Concentration (%) in CAC-717 | CAC-717 + HEPES 1 | DW | Maintenance Medium | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 5 | 10 | 20 | 30 | 40 | 50 | ||||
| IBRV pH | 12.4 | 12.3 | 12.2 | 12.0 | 11.7 | 11.3 | 10.9 | 7.3 | 5.9 | 7.5 |
| viral titer 2 | ≤0.58 * | ≤0.58 * | ≤0.58 * | 2.21 * | 6.58 | 6.33 | 6.83 | 7.08 ± 0.25 | 7.08 ± 0.25 | 6.96 ± 0.13 |
| BAdV-7 pH | 12.3 | 12.2 | 12.1 | 11.8 | 11.4 | 11.0 | 10.5 | 7.3 | 5.8 | 7.5 |
| viral titer | ≤0.58 * | ≤0.58 * | 2.46 ** | 5.83 | 6.96 | 6.33 | 6.46 | 6.46 ± 0.13 | 6.46 ± 0.38 | 6.21 ± 0.13 |
1 Nine volumes of CAC-717 were pretreated with one volume of 1.0 M HEPES buffer (pH 7.2). 2 Log10 TCID50/25 μL (mean ± SE); * A reduction in viral titer of ≥4 log10 relative to treatment with maintenance medium; ** A reduction in viral titer of ≥3 log10 relative to treatment with maintenance medium.
Genome quantification of DNA and RNA viruses treated with CAC-717 for 60 min.
| Genome | Envelope | Family | Viruses | Solution | |
|---|---|---|---|---|---|
| CAC-717 | DW | ||||
| DNA | + |
| PrV | 68.8 ± 3.5 1 | 121.4 ± 7.2 |
| CHV-1 | 82.4 ± 2.8 | 96.6 ± 5.0 | |||
| IBRV | 35.8 ± 4.6 | 91.4 ± 7.5 | |||
| EHV-1 | 8.7 ± 0.4 | 106.8 ±0.9 | |||
| − |
| CPV-2 | 131.0 ± 12.5 | 79.6 ± 2.1 | |
|
| BAdV-7 | 70.2 ± 5.6 | 93.4 ± 2.0 | ||
| RNA | + |
| BPIV-3 | 3.0 ± 0.3 | 90.6± 2.1 |
| BRSV | 0.0 ± 0.0 | 114.6 ± 3.4 | |||
| CDV | 0.0 ± 0.0 | 102.5 ± 1.2 | |||
| NDV | 2.9 ± 0.1 | 119.4 ± 5.4 | |||
|
| VSV | 0.0 ± 0.0 | 105.1 ± 9.9 | ||
|
| SARS-CoV-2 | 88.5 ± 0.8 | 108.7 ± 0.7 | ||
| BCoV | 2.4 ± 0.3 | 97.4 ± 4.7 | |||
|
| BVDV-I | 68.4 ± 2.9 | 109.6 ± 11.8 | ||
| BVDV-II | 22.0 ± 1.6 | 100.4 ± 2.5 | |||
|
| SwIV (H1N1) | 6.6 ± 0.1 | 107.2 ± 0.8 | ||
| EqIV (H3N8) | 0.3 ± 0.0 | 40.3 ± 0.4 | |||
| − |
| BRBV | 0.6 ± 0.1 | 75.0 ± 2.4 | |
|
| FCV | 0.0 ± 0.0 | 82.0± 1.3 | ||
|
| BRoV | 0.0 ± 0.0 | 137.1 ± 3.3 | ||
| BuORV | 0.1 ± 0.0 | 134.1 ± 3.1 | |||
1. Values are the mean ± SE percentage of the copy number of genomes extracted from samples treated with maintenance medium.
Direct application of CAC-717 to genomes of the viruses whose DNA or RNA was not significantly affected by CAC-717 application to virions.
| Viral Genomes | CAC-717 |
|---|---|
| PrV DNA | 0.07 ± 0.01 1 |
| CPV-2 DNA | 0.06 ± 0.01 |
| BVDV-I RNA | 0.03 ± 0.00 |
| BVDV-II RNA | 0.00 ± 0.00 |
1 Values are the mean ± SE percentage of the copy number of genomes extracted from samples treated with DW.
Virucidal effect of CAC-717 on IBRV after long-term storage at room temperature.
| Lot no. | Storage Period | Initial pH Value | pH Value after Storage | Log10 TCID50/25 μL (Mean ± SE) | |||||
|---|---|---|---|---|---|---|---|---|---|
| CAC-717 | CAC-717 + HEPES 1 | Maintenance Medium | |||||||
| 2 s | 10 s | 30 s | 1 min | 1 min | 1 min | ||||
| A (7 January 2015) | 6 y 4 m | 12.4 | 12.4 | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | 7.21 ± 0.13 | 7.08 ± 0.25 |
| B (17 October 2016) | 4 y 7 m | 12.4 | 12.4 | ≤0.58 * | ≤0.58 * | ≤0.58 * | ≤0.58 * | 6.96 ± 0.13 | 6.71 ± 0.13 |
1 Nine volumes of CAC-717 were pretreated with one volume of 1.0 M HEPES buffer (pH 7.2). * A reduction in viral titer of ≥4 log10 relative to treatment with maintenance medium.